

**Saturday, July 14 2018**

**8 am - 1 pm**

**Rudd Heart & Lung Center**

201 Abraham Flexner Way,  
Louisville, KY 40202

**Top researchers and practitioners in neuro-oncology** will share innovative treatment options and alternate delivery techniques with specialists in neuro-oncology, neurology, radiation oncology, medical oncology, neurosurgery, PM&R and palliative care, as well as nurses and allied health professionals, patients and caregivers. Attendees will have a rare opportunity to hear and meet some of the most renowned researchers and clinicians in the nation.



**Course directors:**

**Eric Burton, MD**

*Associate Professor, Department of Neurology,  
University of Louisville  
Director of Neuro-oncology,  
UofL James Graham Brown Cancer Center*



**Brian Williams, M.D.**

*Assistant Professor, Department of  
Neurological Surgery  
University of Louisville*

## AGENDA

**8:00 am** Updates in immunotherapy for primary glioma

**John Villano, MD, PhD**  
University of Kentucky

**9:00 am** Medical therapy for metastatic brain disease

**Manmeet Ahluwalia, MD**  
Cleveland Clinic

**10:15 am** Surgical neuro-oncology

**Brian Williams, MD**  
University of Louisville

**10:50 am** Surgery for metastatic spine disease

**Brian Williams, MD**  
University of Louisville

**11:40 pm** Questions and **Adjourn CME Event**

*Speaker biographies on next page*

**11:45 - 12:45 am** Molecular neuro-oncology **NO CME Offered**

**William Weiss, MD, PhD**  
University of California - San Francisco



**Register at <http://bit.ly/UofLNeuroOnc18>**

**For more information, contact Tess Ocean at [tess.ocean@louisville.edu](mailto:tess.ocean@louisville.edu) or 502-852-3285**



### **Manmeet S. Ahluwalia, MD**

The Dean and Diane Miller Family Endowed Chair in NeuroOncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Ahluwalia subspecializes in treatment of patients with brain tumors and brain metastases. He is a professor and serves as the director, Brain Metastasis Research Program and head of operations in the BBTC of the Neurological Institute of Cleveland Clinic. He is leading several clinical trials involving immune therapy, new targeted therapies as well as treatments targeting tumor blood vessels (angiogenesis) and cancer stem cells. His results have been presented nationally and internationally and have resulted in over 100 manuscripts. Ahluwalia has received multiple awards, including the National Cancer Institute/CTEP Career Development Award for Clinical Trial in American Brain Tumor Consortium and the American Society of Clinical Oncology (ASCO) Leadership Development Program award.



### **John L. Villano, MD, PhD**

A professor of medicine at the University of Kentucky and director of the UK Clinical Neuro-Oncology Program, Villano has expertise in brain tumors by providing clinical epidemiological descriptions, molecular profiling characterizations and participating in practice changing studies. He is a member of the Neuro-Oncology Committee in the cooperative group Alliance for Clinical Trials in Oncology and collaborates with investigators at Kentucky Cancer Registry (KCR) and at Central Brain Tumor Registry of the United States (CBTRUS). He was on the Cancer Education Committee for ASCO on Central Nervous System Tumors and has extensive publications in the field. He conducts clinical trials in neuro-oncology, including both primary and metastatic brain tumors, leading current efforts on investigating immunotherapy by UK.



### **Brian Williams, MD**

An assistant professor in the Department of Neurological Surgery at the University of Louisville, Williams has special expertise in treating primary and metastatic tumors of the brain, spine and skull base. Awards recognizing his excellence in research include the Integra Foundation Award from the Congress of Neurological Surgeons and the Crutchfield Gage Award from the Neurosurgical Society of the Virginias. His laboratory effort focuses on understanding the stem cell biology of glioblastoma tumor cells and the role of hypoxia signaling in peritumoral edema.



### **Speaker for Presentation with No CME Offered**

### **William A. Weiss, MD, PhD**

A professor in the Departments of Neurology, Pediatrics, and Neurological Surgery at the University of California, San Francisco, Weiss is co-leader of the Pediatric Malignancies Program in the UCSF Helen Diller Family Comprehensive Cancer Center and is the Evelyn and Mattie Anderson Endowed Chair in Cancer Research. His lab has developed genetically engineered mouse and other models for tumors of the nervous system, including glioma, medulloblastoma and neuroblastoma.